Timothy McGraw

About

Timothy McGraw, Ph.D., is a Professor of Biochemistry and Biophysics at Weill Cornell Medicine. His laboratory utilizes quantitative optical microscopy to study insulin-regulated membrane trafficking, with a focus on characterizing the GLUT4 trafficking pathway in the presence and absence of insulin. The research aims to understand how insulin-signal transduction regulates the movement of GLUT4 vesicles. Additionally, his lab investigates fundamental questions of membrane trafficking, including the molecular mechanisms of clathrin-mediated internalization from the cell surface and the processes involved in returning endocytosed proteins back to the plasma membrane. His work contributes to a deeper understanding of membrane biology and cellular trafficking mechanisms.

Research topics

• Internal medicine
• Medicine
• Endocrinology
• Oncology
• Biology

Selected publications

• Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial

  The Lancet Oncology · 2021 · 326 citations

  DOI

• Insulin action in adipocytes, adipose remodeling, and systemic effects

  Cell Metabolism · 2021 · 152 citations

  PublisherOA PDFDOI

• Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial

  Nature Communications · 2023-12-19 · 39 citations

  articleOpen accessSenior authorCorresponding

  We previously reported the results of a randomized phase II trial (NCT02904954) in patients with early-stage non-small cell lung cancer (NSCLC) who were treated with either two preoperative cycles of the anti-PD-L1 antibody durvalumab alone or combined with immunomodulatory doses of stereotactic radiation (DRT). The trial met its primary endpoint of major pathological response, which was significantly higher following DRT with no new safety signals. Here, we report on the prespecified secondary…

  PublisherOA PDFDOI

• Deficiency of metabolic regulator PKM2 activates the pentose phosphate pathway and generates TCF1+ progenitor CD8+ T cells to improve immunotherapy

  Nature Immunology · 2024-09-26 · 37 citations

  articleOpen access
  PublisherOA PDFDOI

• TIMP1 is an early biomarker for detection and prognosis of lung cancer

  Clinical and Translational Medicine · 2023-09-27 · 37 citations

  articleOpen access

  BACKGROUND: Lung cancer remains the major cause of cancer-related deaths worldwide. Early stages of lung cancer are characterized by long asymptomatic periods that are ineffectively identified with the current screening programs. This deficiency represents a lost opportunity to improve the overall survival of patients. Serum biomarkers are among the most effective strategies for cancer screening and follow up. METHODS: Using bead-based multiplexing assays we screened plasma and tumours of the Kr…

  PublisherOA PDFDOI

Recent grants

• NIH Grant R01DK069982

  NIH · $1.3M · 2011

• NIH Grant R01DK052852

  NIH · $6.8M · 2017

• NIH Grant R01DK098002

  NIH · $2.4M · 2017

Frequent coauthors

• Nasser K. Altorki

  Cornell University

  233 shared

• Olivier Elemento

  Weill Cornell Medicine

  134 shared

• Vivek Mittal

  Cornell University

  124 shared

• Brendon M. Stiles

  Albert Einstein College of Medicine

  101 shared

• Alain Borczuk

  81 shared

• Jeffrey L. Port

  University Medical Center Hamburg-Eppendorf

  70 shared

• Ashish Saxena

  63 shared

• Silvia C. Formenti

  Weill Cornell Medicine

  54 shared

Similar researchers at Cornell University

• Frederick R. Maxfieldh-108
• David Eliezerh-66
• Anant Menonh-60